SCHEMBL30833145

SCHEMBL30833145

CC(C)(C)OC(=O)N1CCN(c2cc(F)cnc2C2=CCOCC2)CC1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 2/20 0.42
SKP1 P63208 2/20 0.42
SKP2 Q13309 2/20 0.42
GPR119 Q8TDV5 7/20 0.41
TBK1 Q9UHD2 1/20 0.39
SMARCA2 P51531 1/20 0.39
SMARCA4 P51532 1/20 0.39
PBRM1 Q86U86 1/20 0.39
ALK Q9UM73 1/20 0.38
USP2 O75604 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PIK3CA P42336 1/20 0.37
GRM5 P41594 2/20 0.37
GRM1 Q13255 2/20 0.37
LMNA P02545 1/20 0.37
GRIA1 P42261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30833102 0.88 CKS1B (0.42) CKS1BSKP1SKP2GPR119TBK1
SCHEMBL31378528 0.76 GPR119 (0.49) CKS1BSKP1SKP2GPR119SMARCA2
SCHEMBL30833113 0.76 PIK3CA (0.49) CKS1BSKP1SKP2GPR119SMARCA2
SCHEMBL26113732 0.75 POLB (0.49) CKS1BSKP1SKP2GPR119SMARCA2
SCHEMBL30833118 0.75 GPR119 (0.48) CKS1BSKP1SKP2GPR119SMARCA2
SCHEMBL30515311 0.75 TBK1 (0.43) CKS1BSKP1SKP2GPR119TBK1
SCHEMBL31651742 0.74 GPR119 (0.47) CKS1BSKP1SKP2GPR119SMARCA2
SCHEMBL30833112 0.74 PIK3CA (0.48) CKS1BSKP1SKP2GPR119SMARCA2
SCHEMBL24989545 0.73 GPR119 (0.47) CKS1BSKP1SKP2GPR119SMARCA2
SCHEMBL22328950 0.72 GRM1 (0.57) GRM5GRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098026-A1 M4 ACTIVATORS/MODULATORS AND USES THEREOF CEREVEL THERAPEUTICS LLC (US) 2026-04-09 US disclosed
EP-4587432-A1 M4 ACTIVATORS/MODULATORS AND USES THEREOF Cerevel Therapeutics, LLC (US) 2025-07-23 EP disclosed
WO-2024059249-A1 M4 ACTIVATORS/MODULATORS AND USES THEREOF CEREVEL THERAPEUTICS, LLC (US) 2024-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260098026-A1 M4 ACTIVATORS/MODULATORS AND USES THEREOF CHRM1, CHRM2, CHRM4 CKS1B 922/4885SKP1 799/4885SKP2 1677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.